Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis, 2016 Update

Date: August 10, 2016
Pages: 41
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RBA51EB384EEN
Leaflet:

Download PDF Leaflet

Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis, 2016 Update
Summary

Rosetta Genomics Ltd (RGL) is a biotechnology company that develops next generation diagnostic tests for personalized medicine. The company offers testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It is developing tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It has presence in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Rosetta Genomics, Ltd.
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
  • Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
  • Rosetta Genomics, Ltd. Company Snapshot
    Rosetta Genomics, Ltd. Company Overview
    Rosetta Genomics, Ltd. Pipeline Products and Clinical Trials Overview
    Rosetta Genomics, Ltd. – Pipeline Analysis Overview
    Key Facts
    Rosetta Genomics, Ltd. - Major Products and Services
    Rosetta Genomics, Ltd. Pipeline Products by Development Stage
    Rosetta Genomics, Ltd. Pipeline Products Overview
    Body Fluids-Based Diagnostic Test - Cancer
    Body Fluids-Based Diagnostic Test - Cancer Product Overview
    microRNA Test - Alzheimer’s Disease
    microRNA Test - Alzheimer’s Disease Product Overview
    microRNA Test - Bladder Cancer Risk Stratification
    microRNA Test - Bladder Cancer Risk Stratification Product Overview
    microRNA Test - Endometrial Cancer Stratification
    microRNA Test - Endometrial Cancer Stratification Product Overview
    microRNA Test - Gastric Cancer Recurrence
    microRNA Test - Gastric Cancer Recurrence Product Overview
    microRNA Test - Heart Failure
    microRNA Test - Heart Failure Product Overview
    microRNA Test - Ovarian Cancer
    microRNA Test - Ovarian Cancer Product Overview
    microRNA Test - Preeclampsia
    microRNA Test - Preeclampsia Product Overview
    microRNA-Based Assay - Chronic Allograft Dysfunction
    microRNA-Based Assay - Chronic Allograft Dysfunction Product Overview
    microRNA-Based Assay - Neuromuscular Diseases
    microRNA-Based Assay - Neuromuscular Diseases Product Overview
    microRNA-Based Assay - Neuromuscular Dystrophies
    microRNA-Based Assay - Neuromuscular Dystrophies Product Overview
    microRNA-Based Diagnostic Test - Melanoma
    microRNA-Based Diagnostic Test - Melanoma Product Overview
    miRscreen Test - Colon Cancer
    miRscreen Test - Colon Cancer Product Overview
    Prelude DCIS - Breast Cancer
    Prelude DCIS - Breast Cancer Product Overview
    ROS1 Lung Cancer Biomarker
    ROS1 Lung Cancer Biomarker Product Overview
    Rosetta Genomics, Ltd. - Key Competitors
    Rosetta Genomics, Ltd. - Key Employees
    Rosetta Genomics, Ltd. - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries
    Recent Developments
    Rosetta Genomics, Ltd., Recent Developments
    Aug 02, 2016: Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health Network for Entire Suite of Diagnostic Tests and Services
    Jul 11, 2016: Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment
    Jun 23, 2016: Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
    Jun 21, 2016: Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays
    May 26, 2016: Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay
    May 23, 2016: Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays
    May 19, 2016: Rosetta Genomics Reports 2016 First Quarter Financial Results
    Mar 23, 2016: Rosetta Genomics Reports 2015 Full Year Financial Results
    Feb 29, 2016: Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development
    Feb 18, 2016: Rosetta Genomics Receives Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay
    Appendix
    Methodology
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Rosetta Genomics, Ltd. Pipeline Products and Clinical Trials Overview
    Rosetta Genomics, Ltd. Pipeline Products by Equipment Type
    Rosetta Genomics, Ltd. Pipeline Products by Indication
    Rosetta Genomics, Ltd., Key Facts
    Rosetta Genomics, Ltd., Major Products and Services
    Rosetta Genomics, Ltd. Number of Pipeline Products by Development Stage
    Rosetta Genomics, Ltd. Pipeline Products Summary by Development Stage
    Body Fluids-Based Diagnostic Test - Cancer - Product Status
    Body Fluids-Based Diagnostic Test - Cancer - Product Description
    microRNA Test - Alzheimer’s Disease - Product Status
    microRNA Test - Alzheimer’s Disease - Product Description
    microRNA Test - Bladder Cancer Risk Stratification - Product Status
    microRNA Test - Bladder Cancer Risk Stratification - Product Description
    microRNA Test - Endometrial Cancer Stratification - Product Status
    microRNA Test - Endometrial Cancer Stratification - Product Description
    microRNA Test - Gastric Cancer Recurrence - Product Status
    microRNA Test - Gastric Cancer Recurrence - Product Description
    microRNA Test - Heart Failure - Product Status
    microRNA Test - Heart Failure - Product Description
    microRNA Test - Ovarian Cancer - Product Status
    microRNA Test - Ovarian Cancer - Product Description
    microRNA Test - Preeclampsia - Product Status
    microRNA Test - Preeclampsia - Product Description
    microRNA-Based Assay - Chronic Allograft Dysfunction - Product Status
    microRNA-Based Assay - Chronic Allograft Dysfunction - Product Description
    microRNA-Based Assay - Neuromuscular Diseases - Product Status
    microRNA-Based Assay - Neuromuscular Diseases - Product Description
    microRNA-Based Assay - Neuromuscular Dystrophies - Product Status
    microRNA-Based Assay - Neuromuscular Dystrophies - Product Description
    microRNA-Based Diagnostic Test - Melanoma - Product Status
    microRNA-Based Diagnostic Test - Melanoma - Product Description
    miRscreen Test - Colon Cancer - Product Status
    miRscreen Test - Colon Cancer - Product Description
    Prelude DCIS - Breast Cancer - Product Status
    Prelude DCIS - Breast Cancer - Product Description
    ROS1 Lung Cancer Biomarker - Product Status
    ROS1 Lung Cancer Biomarker - Product Description
    Rosetta Genomics Ltd, Key Employees
    Rosetta Genomics Ltd, Other Locations
    Rosetta Genomics Ltd, Subsidiaries

    LIST OF FIGURES

    Rosetta Genomics, Ltd. Pipeline Products by Equipment Type
    Rosetta Genomics, Ltd. Pipeline Products by Development Stage
    Skip to top


    Ask Your Question

    Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis, 2016 Update
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: